Oral Decitabine and Tetrahydrouridine

DRUG2 trials

Sponsors

Yogen Saunthararajah, Clinical Hub for Interventional Research (CHOIR)

Conditions

CCUS Clonal Cytopenia of Undetermined SignificanceClonal Cytopenia of Uncertain SignificanceClonal HematopoiesisSickle Cell Disease

Phase 1

Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease

CompletedNCT01685515

Yogen SaunthararajahSickle Cell Disease

Start: 2012-08-31End: 2018-06-30Updated: 2018-09-11

Phase 2

Modulation of Stem Cell Differentiation in Individuals With High Risk Clonal Haematopoiesis

Not yet recruitingNCT07435636

Clinical Hub for Interventional Research (CHOIR)CCUS Clonal Cytopenia of Undetermined Significance, Clonal Cytopenia of Uncertain Significance, Clonal Hematopoiesis

Start: 2026-04-13End: 2030-10-01Target: 80Updated: 2026-02-27

Related Papers

Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study

PLoS Medicine2017-09-07139 citations

Phase 1 Evaluation of Oral Tetrahydrouridine-Decitabine As Non-Cytotoxic Epigenetic Disease Modification for Sickle Cell Disease

Blood2016-12-022 citations

Combination with Thu to Address Pharmacologic Limitations of Decitabine, Interim PK/PD from a Phase 1/2 Clinical Trial of Oral Thu-Decitabine in Sickle Cell Disease

Blood2014-12-063 citations